Publications
Progression of Vision Loss in Macular Telangiectasia Type 2
Poor long-term outcome of anti-vascular endothelial growth factor therapy in nonproliferative macular telangiectasia type 2
Kupitz EH, Heeren TF, Holz FG, Charbel Issa P. Retina. 2015 Dec;35(12):2619-26.
Ranibizumab for macular telangiectasia type 2 in the absence of subretinal neovascularization
Macular telangiectasia type 2 (MacTel) in a 34-year-old patient
Nicolai H, Wirix M, Spielberg L, Leys A. BMJ Case Rep. 2014 Sep 23;2014. pii: bcr2014204802.
Choroidal thickness in macular telangiectasia type 2
“En face” optical coherence tomography imaging in type 2 idiopathic macular telangiectasia
Multimodal imaging in type 2 idiopathic macular telangiectasia
Sallo FB, Leung I, Clemons TE, Peto T, Bird AC, Pauleikhoff D. Retina. 2015 Apr;35(4):742-9.